Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial
Xiang Hu, Lin Chen, Yian Du, Biao Fan, Zhaode Bu, Xin Wang, Yingjiang Ye, Zhongtao Zhang, Gang Xiao, Fei Li, Qingsi He, Guoli Li, Xian Shen, Bin Xiong, Liming Zhu, Jiwei Liu, Lian Liu, Tao Wu, Jing Zhou, Jun Zhang, Gang Zhao, Xulin Wang, Pin Liang, Xinxin Wang, Yan Zhang, Xiaojiang Wu, Ji Zhang, Xin Ji, Xianglong Zong, Tao Fu, Ziyu Jia, Jiafu Ji, Xiang Hu, Lin Chen, Yian Du, Biao Fan, Zhaode Bu, Xin Wang, Yingjiang Ye, Zhongtao Zhang, Gang Xiao, Fei Li, Qingsi He, Guoli Li, Xian Shen, Bin Xiong, Liming Zhu, Jiwei Liu, Lian Liu, Tao Wu, Jing Zhou, Jun Zhang, Gang Zhao, Xulin Wang, Pin Liang, Xinxin Wang, Yan Zhang, Xiaojiang Wu, Ji Zhang, Xin Ji, Xianglong Zong, Tao Fu, Ziyu Jia, Jiafu Ji
Abstract
Background: The ACTS-GC study had shown postoperative adjuvant therapy with S-1 improved survival of patients with locally advanced gastric cancer. Addition of oxaliplatin to S-1 is considered to be acceptable as one of the treatment options for gastric cancer patients after radical gastrectomy with D2 lymph node excision.
Methods: We have commenced a randomized phase III trial in December 2016 to evaluate S-1 plus oxaliplatin compared with S-1 alone in the adjuvant setting for locally advanced gastric cancer. A total of 564 patients will be accrued from 13 Chinese institutions in two years. The primary endpoint is 3-year relapse-free survival. The secondary endpoints are 5-year overall survival, proportion of patients who complete the postoperative chemotherapy and incidence of adverse events.
Ethic and dissemination: The trial has been approved by the institutional review board of each participating institution and it was activated on December, 2016. The enrollment will be finished in December, 2018. Patient's follow-up will be ended until December, 2023.
Trial registration: ClinicalTrials.gov, identifier: NCT02867839. Registered on August 4, 2016.
Keywords: Locally advanced gastric cancer; S-1 plus oxaliplatin; randomized phase III trial.
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Figures
References
- Torre LA, Bray F, Siegel RL, , et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262. [Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108. <DOI: 10.3322/caac.21262> <PMID: 25651787>]
- Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4) Gastric Cancer. 2017;20:1–19. doi: 10.1007/s10120-016-0622-4. [Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19. <DOI: 10.1007/s10120-016-0622-4> <PMID: 27342689>]
- Lee JH, Kim JG, Jung HK, , et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;14:87–104. doi: 10.5230/jgc.2014.14.2.87. [Lee JH, Kim JG, Jung HK, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer 2014;14:87-104. <DOI: 10.5230/jgc.2014.14.2.87> <PMID: 25061536>]
- Nakajima T, Kinoshita T, Nashimoto A, , et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007;94:1468–76. doi: 10.1002/bjs.5996. [Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007;94:1468-76. <DOI: 10.1002/bjs.5996> <PMID: 17948223>]
- Shitara K, Chin K, Yoshikawa T, , et al. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer. 2017;20:175–81. doi: 10.1007/s10120-015-0581-1. [Shitara K, Chin K, Yoshikawa T, et al. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer 2017;20:175-81. <DOI: 10.1007/s10120-015-0581-1> <PMID: 26626800>]
- Takahari D, Hamaguchi T, Yoshimura K, , et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2011;67:1423–8. doi: 10.1007/s00280-010-1432-8. [Takahari D, Hamaguchi T, Yoshimura K, et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol 2011;67:1423-8. <DOI: 10.1007/s00280-010-1432-8> <PMID: 20809123>]
- Sasako M, Sakuramoto S, Katai H, , et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011; 29 :4387–93. doi: 10.1200/JCO.2011.36.5908. [Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-93. <DOI: 10.1200/JCO.2011.36.5908> <PMID: 22010012>]
- Noh SH, Park SR, Yang HK, , et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96. doi: 10.1016/S1470-2045(14)70473-5. [Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-96. <DOI: 10.1016/S1470-2045(14)70473-5> <PMID: 25439693>]
- Wagner AD, Grothe W, Haerting J, , et al. Chemo-therapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9. doi: 10.1200/JCO.2005.05.0245. [Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9. <DOI: 10.1200/JCO.2005.05.0245> <PMID: 16782930>]
- GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, , et al. Benefit of adjuvant chemo-therapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729–37. doi: 10.1001/jama.2010.534. [GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303:1729-37. <DOI: 10.1001/jama.2010.534> <PMID: 20442389>]
- Tsuburaya A, Yoshida K, Kobayashi M, , et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014;15:886–93. doi: 10.1016/S1470-2045(14)70025-7. [Tsuburaya A, Yoshida K, Kobayashi M, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol 2014;15:886-93. <DOI: 10.1016/S1470-2045(14)70025-7> <PMID: 24954805>]
Source: PubMed